Take­da bumps En­tyvio peak sales, lays out dengue vac­cine plans and celi­ac pipeline in lat­est earn­ings call

Take­da pro­ject­ed op­ti­mism in Thurs­day’s first-half fis­cal earn­ings call across its port­fo­lio, an­nounc­ing a boost in peak sales es­ti­mates for its al­ready block­buster IBD med En­tyvio along with pos­i­tive news on its dengue vac­cine Qden­ga and celi­ac dis­ease pipeline. The pos­i­tive out­look punc­tu­at­ed over­all sales growth on first-half rev­enue of $13.6 bil­lion, up 5.5%.

CEO Christophe We­ber at­trib­uted the growth to strong sales led by En­tyvio (+17%), hered­i­tary an­gioede­ma drug Takhzy­ro (+31%) and plas­ma prod­uct HyQvia (+17%).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER